Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

NCT05896566 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT05896566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05896566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2024
Completion date
September 18, 2025
Enrollment
231 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer